21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

Changes in sleep characteristics in Parkinson's disease: a prospective 5-year follow-up study.

Eemil Partinen, Ari Ylikoski, Christer Hublin, Markku Partinen

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026

Abstract originale

PURPOSE: Sleep disturbances are common and disabling symptoms in Parkinson's disease (PD). Evolution of sleep disturbances in PD remains incompletely characterized. We aimed to describe changes in sleep parameters and sleep disorders over 5 years in a prospective PD cohort. METHODS: A structured sleep questionnaire was administered to members of the Finnish Parkinson's Association at baseline and at 5-year follow-up. Longitudinal changes were analyzed in 183 participants with complete data at both time. RESULTS: Daytime sleepiness increased significantly, with the proportion of participants with Epworth Sleepiness Scale (ESS) > 10 rising from 30.6% to 38.8% (P = 0.026) and daily napping from 21.4% to 31.7% (P = 0.004). Sleep talking (≥ 1/week) increased from 17.4% to 30.4% (P < 0.001), nightmares from 14.8% to 24.6% (P = 0.003), and mean, REM Sleep Behavior Disorder Screening Questionnaire score (RBDSQ) from 4.4 to 5.3 points (P < 0.001). Restless legs syndrome (RLS) prevalence increased from 21.0% to 31.2% (P = 0.038). In contrast, insomnia symptoms, circadian timing and total sleep time remained stable. In multivariate logistic regression, excessive daytime sleepiness was independently associated with depressive symptoms, use of dopamine agonists, and risk of sleep apnea. CONCLUSION: Sleep disturbances in PD show a selective pattern of progression over 5 years. Daytime sleepiness, napping, RLS symptoms, sleep talking, nightmares and RBDSQ score increase while insomnia symptoms remain stable. These findings highlight the need for longitudinal, multi-domain sleep assessment in PD clinical care. The longitudinal increase in RBD-related symptoms and sleep talking strengthens their utility as markers of disease progression and clinical prognostic relevance. CURRENT KNOWLEDGE/STUDY RATIONALE: Sleep disturbances are among the most frequent and disabling non-motor symptoms of Parkinson's disease. These include insomnia, excessive daytime sleepiness, REM sleep behavior disorder, and restless legs syndrome. Long-term prospective data on how multiple sleep disorders and sleep characteristics evolve over time in PD is lacking. STUDY IMPACT: In this 5-year prospective cohort study sleep disturbances in PD progress selectively. Daytime sleepiness, napping, restless legs syndrome, sleep talking, nightmares and RBD-related features worsen significantly while insomnia symptoms remain stable. This provides evidence that sleep characteristics and disorders evolve in time. Sleep disturbances in PD should be assessed routinely in clinical practice.

Parole chiave

HumansParkinson DiseaseMaleProspective StudiesFollow-Up StudiesFemaleAgedSurveys and QuestionnairesSleep Wake DisordersMiddle AgedFinlandRestless Legs SyndromeSleep DurationREM Sleep Behavior DisorderDisease ProgressionExcessive daytime sleepinessFollow-upInsomniaParkinson’s diseaseSleep disordersSleep talking
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Changes in sleep characteristics in Parkinson’s disease: a prospective 5-year follow-up study

Purpose

Sleep disturbances are common and disabling symptoms in Parkinson’s disease (PD). Evolution of sleep disturbances in PD remains incompletely characterized. We aimed to describe changes in sleep parameters and sleep disorders over 5 years in a prospective PD cohort.

Methods

A structured sleep questionnaire was administered to members of the Finnish Parkinson’s Association at baseline and at 5-year follow-up. Longitudinal changes were analyzed in 183 participants with complete data at both time.

Results

Daytime sleepiness increased significantly, with the proportion of participants with Epworth Sleepiness Scale (ESS) > 10 rising from 30.6% to 38.8% (P = 0.026) and daily napping from 21.4% to 31.7% (P = 0.004). Sleep talking (≥ 1/week) increased from 17.4% to 30.4% (P < 0.001), nightmares from 14.8% to 24.6% (P = 0.003), and mean, REM Sleep Behavior Disorder Screening Questionnaire score (RBDSQ) from 4.4 to 5.3 points (P < 0.001). Restless legs syndrome (RLS) prevalence increased from 21.0% to 31.2% (P = 0.038). In contrast, insomnia symptoms, circadian timing and total sleep time remained stable. In multivariate logistic regression, excessive daytime sleepiness was independently associated with depressive symptoms, use of dopamine agonists, and risk of sleep apnea.

Conclusion

Sleep disturbances in PD show a selective pattern of progression over 5 years. Daytime sleepiness, napping, RLS symptoms, sleep talking, nightmares and RBDSQ score increase while insomnia symptoms remain stable. These findings highlight the need for longitudinal, multi-domain sleep assessment in PD clinical care. The longitudinal increase in RBD-related symptoms and sleep talking strengthens their utility as markers of disease progression and clinical prognostic relevance.

Brief summary

Current knowledge/study rationale

Sleep disturbances are among the most frequent and disabling non-motor symptoms of Parkinson’s disease. These include insomnia, excessive daytime sleepiness, REM sleep behavior disorder, and restless legs syndrome. Long-term prospective data on how multiple sleep disorders and sleep characteristics evolve over time in PD is lacking.

Study impact

In this 5-year prospective cohort study sleep disturbances in PD progress selectively. Daytime sleepiness, napping, restless legs syndrome, sleep talking, nightmares and RBD-related features worsen significantly while insomnia symptoms remain stable. This provides evidence that sleep characteristics and disorders evolve in time. Sleep disturbances in PD should be assessed routinely in clinical practice.

Graphical Abstract

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s44470-026-00169-6.

Introduction

Sleep disturbances are among the most frequent non-motor symptoms of Parkinson’s disease (PD) [1, 2]. They may emerge years before motor symptom onset and tend to worsen as the disease progresses [3–5]. A wide range of sleep-related problems are observed in PD, including insomnia, excessive daytime sleepiness, REM sleep behavior disorder (RBD) and restless legs syndrome (RLS) [2, 6, 7]. These disturbances can interact with each other and with other non-motor symptoms such as depression, fatigue, and cognitive decline, substantially affecting quality of life [2, 8, 9].

Shortening of sleep duration, deterioration of sleep and longer sleep duration have been associated with an increased risk of developing PD [4, 10]. In our previous work within the same cohort, we demonstrated that sleep talking, a potential marker of REM sleep behavior disorder (RBD), and longer sleep duration were both linked to higher mortality in patients with PD [7, 11]. These findings suggest that alterations in sleep duration and specific sleep-related behaviors may reflect underlying neurodegenerative processes relevant to disease prognosis.

However, most earlier studies have examined single sleep symptoms in isolation, typically in cross-sectional or short-term designs. As a result, the long-term evolution and interrelationships of multiple sleep disorders and sleep parameters in PD remain incompletely understood.

To address this gap, we conducted a 5-year prospective follow-up study to characterize changes in key sleep parameters and disorders, including sleep duration, chronotype, insomnia, RLS, snoring, sleep talking, RBD and sleep apnea.

We hypothesized that sleep duration and daytime sleepiness would increase during 5 years, and that the prevalence of sleep talking would rise in parallel with disease progression.

Methods

From the 7500 members of the Finnish Parkinson’s Association 5373 were registered as PD patients. A random sample of 1500 subjects was selected from these registered PD patients. A structured questionnaire was sent to 1447 eligible participants between 2010 and 2011. Inclusion criteria were Parkinson’s disease diagnosis confirmed by a neurologist, ability to consent, and being alive at baseline. In Finland, PD diagnosis is established by a specialist neurologist and follows national clinical guidelines consistent with the Gelb diagnostic criteria [12, 13]. Diagnoses were self-reported as neurologist-confirmed and were not re-verified by medical record review. The questionnaire was designed for PD patients, with sleep-related items from the validated Basic Nordic Sleep Questionnaire (BNSQ) [14]. Further details of the cohort and survey have been published previously [15]. Consenting participants were sent a follow-up questionnaire in 2014 to 2015. Non-respondents were reminded and telephoned. Altogether, 183 subjects responded to all questions used in the study.

Age was calculated from date of birth to questionnaire date. Gender was recorded as female or male. Body mass index (BMI) was calculated from self-reported height and weight. Health-related quality of life was defined as poor when the standardized WHO-5 Well-Being Index score was < 50 [16]. Education level was determined based on total duration of school education (basic and higher). Weekly metabolic equivalent values in minutes (MET-minutes) were derived from self-reported physical activity. Participants were categorized as sedentary (< 100), moderately active (100 – < 1000), or highly active (≥ 1000 MET-minutes) [17].

Total daily levodopa equivalent dose (LED) was computed using standard conversion factors for each self-reported medication [18]. Olfactory dysfunction was defined as a subjectively reduced sense of smell compared to others, constipation as infrequent bowel movements (≤ 3 per week), and nocturia as the need to urinate ≥ 3 times per night. Depressive symptoms were screened with Rimon’s Brief Depression Scale, using a score ≥ 10 to indicate depression. The scale excludes insomnia symptoms, is validated against the Beck Depression Inventory, and is available in Finnish [19]. Regular use of sleep medication was defined as use on ≥ 3 nights per week. Sleep attacks were measured with a question “Have you suffered from a compulsive tendency to fall asleep (an irresistible urge to fall asleep) on weekdays/working days?”. Sleep attacks was considered present if they were reported on ≥ 3 days per week. We also used the Epworth Sleepiness Scale (ESS) to assess sleepiness [20]. Daytime fatigue was assessed using a question “Have you felt tired during the daytime?”. Cut-off for fatigue was ≥ 3 days per week. Sleep-disordered breathing risk was assessed with the STOP questionnaire, using a score ≥ 2 as the cutoff for high risk of sleep apnea [21]. Insomnia symptoms such as difficulty initiating sleep (cut off ≥ 3 times per week), nocturnal awakenings during the night (cut off ≥ 3 times per night), early morning awakenings (cut off ≥ 3 times per week) and non-restorative sleep were assessed on a five-point frequency scale (as in BNSQ). A binary composite variable capturing any insomnia symptom was defined as the presence of at least one of the following: Difficulty initiating sleep, nocturnal awakenings, early morning awakenings, non-restorative sleep, or regular use of sleep aids. RLS was defined according to the international 4-item definition criteria [22]. REM sleep behavior disorder (RBD) symptoms were screened with the RBD Screening Questionnaire (RBDSQ), with a score ≥ 6 indicating RBD [23]. We used insomnia severity index (ISI) to assess insomnia symptoms at follow-up [24]. Unfortunately, we did not include ISI to baseline questionnaire.

Total sleep time (TST) was calculated from self-reported median sleep duration per 24 h, excluding naps. Circadian timing was estimated using midsleep, a midpoint of sleep calculated from bedtime, sleep latency and time to wake up.

Statistical analyses were performed using STATA 19.5 (StataCorp, USA). Descriptive statistics for continuous variables are presented as means with 95% confidence intervals (CI). The Shapiro–Wilk test was conducted to check for normality in the distributions. To assess potential selection bias, we compared baseline characteristics of follow-up cohort (n = 183) with the full baseline cohort (n = 611). Independent-samples comparisons were performed using the Mann–Whitney two sample statistic test for continuous variables and the chi-square test for categorical variables, with Fisher’s exact test applied where expected cell counts were less than five. Longitudinal changes in continuous and categorical variables were compared using the Wilcoxon signed-rank test. To identify clinical and demographic factors associated with excessive daytime sleepiness at follow-up, we performed univariate and multivariate logistic regression analyses with ESS > 10 as the dependent variable. Daytime sleepiness was selected as the primary outcome for regression analysis because it showed a clinically and statistically significant increase over the follow-up period and is a symptom of particular functional relevance in PD. All candidate variables were measured at follow-up and included age, sleep duration, depression score, LED, use of dopamine agonists, risk of sleep apnea, RBDSQ-score. All variables were entered into the multivariate model. Results are presented as odds ratios (OR) with 95% CI. Statistical significance was set at P < 0.05.

Results

Subjects in the follow-up cohort were younger, had shorter disease duration, higher BMI, and better health-related quality of life compared to those who did not complete follow-up or had missing data. Gender, LED, olfactory dysfunction, constipation, and depression prevalence did not differ significantly between groups. Please see Supplementary Table 1 for a comparison of baseline characteristics between included and excluded subjects.

Demographics and other characteristics of the cohort are presented in Table 1.
Table 1Characteristics of the cohort

All at baseline;N = 611(95% CI) Baseline (5 y fup cohort); n = 183 (95% CI) Follow-up (5 y fup cohort); n = 183 (95% CI) P-value (Baseline vs fup)

Age (years) 67.9 (66.2–68.6) 65.6 (64.4–66.8) 69.7 (68.5–70.9)  < 0.001*

Gender (men, %) 54.2 (50.1–58.2) 52.5 (45.0–59.9) 52.5 (45.0–59.9) 1

BMI (kg/m2) 26.5 (26.1–26.8) 27.2 (26.5–27.9) 26.8 (26.0–27.5) 0.051

Education ≤ 9 years (%) 41.0 (37.0–45.0) 38.3 (31.2–45.7) 38.3 (31.2–45.7) 1

Education > 9 to ≤ 12 years (%) 42.1 (38.1–46.2) 45.4 (38.0–52.9) 45.4 (38.0–52.9) 1

Education > 12 years (%) 16.9 (14.0–20.1) 16.4 (11.3–22.6) 16.4 (11.3–22.6) 1

Mean physical activity (MET-min) 571.7 (524.2–619.1) 600.7 (506.9–694.5) 469.0 (401.6–536.5) 0.022*

Sedentary (MET < 100, %) 15.6 (12.8–18.8) 9.0 (5.3–14.3) 18.0 (12.8–24.4) 0.008*

Active (MET ≥ 100 & < 1000, %) 67.9 (64.0–71.7) 74.6 (67.5–80.1) 69.4 (62.2–76.0) 0.317

Highly active (MET ≥ 1000, %) 16.4 (13.6–19.7) 16.4 (11.3–22.7) 12.6 (8.1–18.3) 0.317

Duration of PD (years) 6.3 (5.9–6.6) 5.5 (5.0–6.0) 9.7 (9.1–10.2)  < 0.001*

LED (mg) 644.7 (612.4–677.0) 607.8 (558.0–657.6) 732.6 (675.2–790.1)  < 0.001*

Olfactory dysfunction (%) 67.3 (63.4–71.0) 62.8 (55.4–69.9) 71.0 (63.9–77.5) 0.005*

Constipation 31.6 (27.9–35.4) 29.0 (22.5–36.1) 31.7 (25.0–39.0) 0.484

Poor quality of life (WHO5 < 50, %) 42.2 (38.3–46.3) 33.9 (27.1–41.2) 38.8 (31.7–46.3) 0.225

Depression (%) 27.1 (23.6–30.8) 22.5 (16.7–29.3) 23.5 (17.6–30.3) 0.763

PD Parkinson’s disease, BMI body mass index, LED levodopa equivalent dose, WHO-5 WHO-5 Well-Being Index, MET metabolic equivalent of task; BMI calculated from self-reported height and weight. Physical activity categories: sedentary (MET-minutes/week < 100), moderately active (100 to < 1000), highly active (≥ 1000). LED calculated using standard conversion factors. Olfactory dysfunction defined as subjectively reduced sense of smell compared to others. Constipation defined as ≤ 3 bowel movements per week. Poor quality of life defined as WHO-5 Well-Being Index score < 50. Depression screened using Rimon’s Brief Depression Scale (cut-off ≥ 10); the scale excludes insomnia items and is validated against the Beck Depression Inventory

*Statistical significance P < 0.05. P-value calculated using the Wilcoxon signed-rank test

Mean disease duration increased from 5.5 to 9.7 years (P < 0.001). Education levels remained unchanged during follow-up, as no participants pursued further studies. Physical activity decreased during follow-up, with the proportion of sedentary participants rising from 9.0% to 18.0% (P = 0.008). Mean levodopa equivalent dose (LED) increased from 607.8 mg to 732.6 mg (P < 0.001), and olfactory dysfunction increased from 62.8% to 71.0% (P = 0.005). Constipation, depression, and health-related quality of life (WHO-5) remained unchanged during follow-up.

Changes in sleep characteristics are shown in Table 2. Sleep duration showed a non-significant increase from 7.0 to 7.2 h (P = 0.237). Individual insomnia symptoms (difficulty initiating sleep, nocturnal awakenings, early morning awakenings, and non-restorative sleep) did not change significantly over the follow-up period. Also, the composite variable capturing any insomnia symptoms or use of sleep aids remained unchanged. Similarly, daytime fatigue and hallucinations remained stable. In contrast, daytime sleepiness increased significantly: the proportion of participants with an ESS score > 10 rose from 30.6% to 38.8% (P = 0.026), and severe sleepiness (ESS > 15) from 8.9% to 14.8% (P = 0.043). Daily napping increased from 21.4% to 31.7% (P = 0.004). Restless legs syndrome (RLS) prevalence increased from 21.0% to 31.2% (P = 0.038). Sleep talking (≥ 1/week) increased markedly from 17.4% to 30.4% (P < 0.001), and nightmares (≥ 1/week) from 14.8% to 24.6% (P = 0.003). Mean RBDSQ score increased from 4.4 to 5.3 points (P < 0.001), and the proportion meeting the RBDSQ ≥ 6 threshold rose from 28.9% to 39.9% (P = 0.008). Midsleep time and sleep-disordered breathing (OSA) risk (STOP ≥ 2) were unchanged.
Table 2Change of sleep disorders and characteristics in 5-year follow-up

Baseline, n = 183Mean (95% CI) Follow-up, n = 183Mean (95% CI) P-value

Sleep duration (h) 7.0 (6.7–7.2) 7.2 (6.9–7.4) 0.237

Difficulty initiating sleep (%) 29.4 (22.8–36.7) 31.1 (24.5–38.4) 0.636

Nocturnal awakenings (%) 25.8 (19.6–32.8) 28.9 (22.5–36.1) 0.489

Early morning awakenings (%) 39.2 (32.1–46.7) 36.6 (29.6–44.0) 0.568

Non restorative sleep (%) 40.7 (33.4–48.3) 40.6 (33.3–48.1) 1.000

Regular use of sleep medications (%) 15.9 (10.9–22.1) 19.6 (14.0–26.1) 0.178

Any symptoms of insomnia (%) 67.8 (60.1–74.6) 68.9 (62.1–75.6) 0.885

Midsleep (am) 2:36 (2:30–2:48) 2:42 (2:30–2:54) 0.203

Sleep attacks (%) 25.3 (19.1–32.3) 28.3 (21.9–35.5) 0.189

ESS > 10 (%) 30.6 (23.9–37.8) 38.8 (31.7–46.3) 0.026*

ESS > 15 (%) 8.9 (5.2–14.0) 14.8 (10.0–20.7) 0.043*

Daily naps (%) 21.4 (15.7–28.1) 31.7 (25.0–39.0) 0.004*

Daytime fatigue (%) 53.3 (45.8–60.8) 54.2 (46.6–61.6) 1.000

RLS (%) 21.0 (14.5–28.8) 31.2 (24.1–39.1) 0.038*

STOP ≥ 2 (%) 42.1 (34.8–49.6) 38.3 (31.2–45.7) 0.317

Sleep talking ≥ 1/w (%) 17.4 (12.2–23.8) 30.4 (23.8–37.6)  < 0.001*

Nightmares ≥ 1/w (%) 14.8 (9.9–20.9) 24.6 (18.5–31.6) 0.003*

Hallucinations ≥ 1/w (%) 11.9 (7.5–17.7) 15.8 (10.9–22.0) 0.411

Nocturia (%) 14.3 (9.5–20.2) 19.1 (13.7–25.6) 0.150

RBDSQ (points) 4.4 (4.0–4.8) 5.3 (4.8–5.7)  < 0.001*

RBDSQ ≥ 6 28.9 (22.4–36.1) 39.9 (32.7–47.4) 0.008*

ESS Epworth Sleepiness Scale, RLS Restless legs syndrome, STOP STOP questionnaire for obstructive sleep apnea screening (score ≥ 2 indicates high risk), RBDSQ REM Sleep Behavior Disorder Screening Questionnaire, w week

Difficulty initiating sleep: ≥ 3 times per week. Nocturnal awakenings: ≥ 3 awakenings per night. Early morning awakenings and non-restorative sleep assessed on a 5-point frequency scale (cut-off ≥ 3 times per week). Any symptoms of insomnia: Any insomnia symptom or use of sleep aids. Sleep attacks: daytime sleepiness on ≥ 3 days per week. Daytime fatigue: fatigue on ≥ 3 days per week. Nocturia: ≥ 3 times per night. Sleep talking and nightmares: occurring at least once per week. Regular use of sleep medications: use on ≥ 3 nights per week. Midsleep time calculated as midpoint between sleep onset and wake time

*Statistical significance P < 0.05. P-values calculated using the Wilcoxon signed-rank test

At follow-up, the mean ISI score was 8.7 (95% CI 7.8–9.5). Applying standard severity thresholds, the majority, 56.9% (95% CI 49.3–64.5), had no clinically significant insomnia (ISI < 10), 28.1% (95% CI 21.3–35.0) had subthreshold insomnia (ISI 10–14), and 15.0% (95% CI 9.5–20.4) met criteria for clinical insomnia (ISI ≥ 15).

Results for logistic regression models for excessive sleepiness at follow up (ESS > 10) are presented in Table 3. In the fully adjusted model depression score, use of dopamine agonist and risk of sleep apnea were associated with excessive daytime sleepiness.
Table 3Logistic regression analysis for excessive daytime sleepiness (ESS > 10)

Univariate model, n = 183Odds ratio (95% CI) P-value Multivariate model, n = 183Odds ratio (95% CI) P-value

Age 0.98 (0.94–1.01) 0.185 0.97 (0.93–1.01) 0.184

Male gender 1.12 (0.61–2.07) 0.716 1.22 (0.60–2.46) 0.587

Sleep duration 0.97 (0.83–1.14) 0.720 0.99 (0.81–1.20) 0.894

RBDSQ score 1.13 (1.03–1.25) 0.011* 1.04 (0.93–1.17) 0.490

Depression score 1.15 (1.06–1.24)  < 0.001* 1.18 (1.07–1.30) 0.001*

LED 1.00 (1.00–1.00) 0.689 1.00 (1.00–1.00) 0.925

Use of dopamine agonist 1.98 (1.01–5.21) 0.047* 3.94 (1.54–10.04) 0.004*

STOP 1.71 (1.25–2.33) 0.001* 1.54 (1.08–2.20) 0.017*

RBDSQ REM Sleep Behavior Disorder Screening Questionnaire; Depression score: Rimon’s Brief Depression Scale as continuous variable, the scale excludes insomnia items and is validated against the Beck Depression Inventory; LED levodopa equivalent dose, STOP STOP questionnaire for obstructive sleep apnea screening

*Statistical significance P < 0.05

In sensitivity analyses, the association between dopaminergic medication use and excessive daytime sleepiness at follow-up was examined in univariate logistic regression models. Neither levodopa OR 0.55 (95% CI 0.18–1.70, P = 0.295) nor MAO inhibitors OR 0.98 (95% CI 0.52–1.83, P = 0.945) were associated with excessive daytime sleepiness. When use of different dopaminergic medication was added to the fully adjusted logistic regression model, higher depression score (OR 1.18, 95% CI 1.07–1.31, P = 0.001), high risk of sleep apnea (STOP ≥ 2; OR 1.53, 95% CI 1.05–2.21, P = 0.025), and use of dopamine agonists (OR 3.92, 95% CI 1.41–10.86, P = 0.009) were independently associated with excessive daytime sleepiness. Age (OR 0.97, 95% CI 0.92–1.01, P = 0.165), total sleep time (OR 0.95, 95% CI 0.77–1.16, P = 0.595), RBDSQ score (OR 1.08, 95% CI 0.95–1.22, P = 0.247), MAO inhibitor use (OR 0.82, 95% CI 0.38–1.77, P = 0.611) and levodopa use (OR 0.52, 95% CI 0.15–1.87, P = 0.319) were not significantly associated with excessive daytime sleepiness.

Discussion

We observed changes in sleep characteristics over a 5-year follow-up period. The most relevant findings were an increase in daytime sleepiness, greater daily napping, a higher prevalence of RLS symptoms, and a marked rise in sleep talking, nightmares, and RBDSQ scores. In contrast, insomnia symptoms, total sleep time, midsleep as a marker of circadian timing and sleep-disordered breathing risk remained stable over the follow-up period. These findings support the idea that specific sleep disturbances in PD may change in time. Contrary to previous findings we did not observe an increase in symptoms of insomnia.

Total sleep time did not change significantly over 5 years, increasing from 7.0 to 7.2 h (P = 0.237). This is broadly consistent with the general pattern of age-related sleep changes. In general population also sleep efficiency declines and nocturnal awakenings become more frequent [25]. However, we did not observe a significant increase in nocturnal awakenings or early morning awakenings, which may partly reflect a survivor effect in our follow-up cohort. The absence of a significant changes in sleep duration is noteworthy given that both prolonged and shorter sleep has been associated with cognitive decline and increased dementia risk in prior studies and longer sleep duration has been linked to higher mortality in this cohort [11, 26].

A contrast to previous finding is that individual insomnia symptoms (difficulty initiating sleep, nocturnal awakenings, early morning awakenings, and non-restorative sleep) did not increase during follow-up. This contrasts with some earlier reports describing insomnia as a common and progressive complaint in PD [5]. A composite variable capturing any insomnia symptom or regular use of sleep aids also remained stable over the follow-up period, suggesting that the modest increase in sleep aid use (15.9% at baseline vs 19.6% at follow-up) does not explain the stability of insomnia symptoms. A possible explanation is that, as disease severity increases, patients may become less distressed by or less aware of fragmented sleep. The availability of ISI scores only at follow-up limits direct longitudinal comparison of insomnia severity using a validated instrument, which should be addressed in future studies. Circadian timing was stable over follow-up period, but circadian propensity is not easily discernible from insomnia features in our questionnaire data.

The progression of RBD-related features, sleep talking and nightmares is among the most clinically significant findings of this study. Sleep talking (≥ 1/week) nearly doubled in prevalence from 17.4% to 30.4% (P < 0.001), and nightmares increased from 14.8% to 24.6% (P = 0.003). Mean RBDSQ score increased significantly, and the proportion meeting the RBDSQ ≥ 6 threshold rose from 28.9% to 39.9% (P = 0.008). RBD is recognized as a core prodromal feature of synucleinopathies and is strongly associated with subsequent cognitive decline and a more malignant PD phenotype [3]. The increase in RBDSQ scores suggests active progression of REM sleep pathology as PD advances. We have previously reported that sleep talking is associated with increased mortality in this cohort [7]. The present longitudinal data reinforce its clinical significance as a marker of disease progression rather than an incidental finding.

Daytime sleepiness increased significantly over 5 years, with a clinically meaningful rise in both pooled excessive sleepiness (ESS > 10) and severe (ESS > 15) sleepiness. The prevalence is in line with other studies [27]. Similarly, daily napping increased, possibly reflecting higher daytime sleepiness. Sleepiness was associated with symptoms of depression, use of dopaminergic drugs and risk of sleep apnea. Other factors may also have contributed to the observed increase in sleepiness, including changes in medications not captured in our regression model, comorbidities, and changes in societal well-being and daily functioning. Nevertheless, this finding highlights the need for addressing secondary reasons for sleepiness.

RLS prevalence increased significantly from 21.0% to 31.2% over 5 years (P = 0.038). RLS in PD shares dopaminergic pathophysiology, although RLS has several other proposed symptom generating mechanisms as well. For example, in GWAS, studies mainly non-dopaminergic risk loci have been identified [28]. Progression of RLS symptoms alongside increasing LED could reflect inadequate drug treatment but also augmentation. The increase in RLS prevalence is broadly consistent with cross-sectional reports of elevated RLS frequency in advanced PD [29, 30].

The stability of sleep-disordered breathing risk (STOP ≥ 2) over 5 years is somewhat unexpected given the progressive motor and autonomic dysfunction in PD. One plausible explanation is that weight loss (reflected by the trend towards lower BMI at follow-up P = 0.051) changes the STOP-score. We highlight that STOP questionnaire captures self-reported symptoms and may lack sensitivity for detecting changes in OSA severity in this population. Objective sleep polygraphy data would be needed to confirm this finding.

Strengths and limitations

The prospective design with a 5-year interval is a key strength, enabling genuine longitudinal characterization of sleep disturbances in an established PD cohort. The use of a structured, validated sleep questionnaire (BNSQ) applied consistently at both time points enhances comparability. The inclusion of multiple sleep domains (insomnia, sleepiness, parasomnias, RLS, chronotype, and sleep-disordered breathing) provides a comprehensive picture of the possible sleep phenotype in PD [31].

Several limitations merit consideration. The follow-up sample (n = 183) is small relative to the baseline cohort (n = 611), as only participants with complete data at both time points were included. This choice introduces a survivor effect: patients who died or were too unwell to complete the follow-up questionnaire are systematically excluded. This bias is supported by finding that subjects in the follow-up cohort were younger, had better QOL and shorter PD duration. This healthy-survivor bias could attenuate the true magnitude of changes in sleep duration, sleepiness, and parasomnias over time, meaning our estimates are probably conservative. We did not have motor symptom measures available, which prevents us from correlating changes in sleep characteristics with changes in core motor symptoms. The baseline sample was randomly selected from the Finnish Parkinson’s Association registry, which covers a large portion of PD patients in Finland, and is considered broadly representative of the Finnish PD population. However, this may result in selection bias towards more active or less severely affected patients. The absence of a healthy control population limits our ability to dissect disease-specific effects from normal age-related sleep changes. As the study was conducted in Finland, cultural differences and healthcare practices may limit the generalizability of these findings to other populations and healthcare settings.

Recall bias may affect self-reported sleep parameters, although its direction is likely consistent across both time points. The reliance on a questionnaire-based approach, without objective sleep recording, means that some diagnoses, particularly RBD and sleep apnea are based on surrogate markers. Also, sleep talking and nightmares could appear as isolated symptoms without relation to RBD. Video-polysomnography would be required for accurate classification of RBD, OSA and other parasomnias. Similarly, PD diagnoses were self-reported as established by a neurologist at baseline but not reverified at follow-up or by reviewing medical records. This is a limitation of large registry-based cohort studies. In Finland, PD diagnosis is largely given by a movement disorder expert or specializing physician under expert supervision. Diagnosis established by a specialist neurologist is a structural requirement of the healthcare system. The national diagnostic criteria applied during the enrolment period (2010–2011) were consistent with the Gelb criteria [12, 13]. Few participants may have received an alternative or revised diagnosis over time and forgot to inform us via the questionnaire. The ISI score was only included at follow-up, forbidding direct longitudinal comparison of insomnia severity using this validated tool.

Conclusions

In this prospective cohort study of patients with Parkinson’s disease, sleep disturbances showed a selective pattern of progression over 5 years. Daytime sleepiness, daily napping, symptoms of RLS, sleep talking, nightmares, and RBDSQ scores increased significantly. In contrast, insomnia symptoms, circadian timing, total sleep duration, and sleep-disordered breathing risk remained unchanged. The increase in sleepiness was associated with symptoms of depression, use of dopamine agonist and the risk of sleep apnea, highlighting the need for addressing these factors in Parkinson patients suffering from sleepiness. The longitudinal increase in RBD-related symptoms and sleep talking strengthens their utility as markers of disease progression and clinical prognostic relevance.

Supplementary Information

Below is the link to the electronic supplementary material.

References

1.Barone P Antonini A Colosimo C Marconi R Morgante L Avarello TP The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease Mov Disord. 2009 24 11 1641 9 10.1002/mds.22643 19514014 Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9. 10.1002/mds.22643 .19514014

2.Ylikoski A Martikainen K Sieminski M Partinen M Parkinson’s disease and insomnia Neurol Sci 2015 36 11 2003 2010 10.1007/s10072-015-2288-9 26099862 Ylikoski A, Martikainen K, Sieminski M, Partinen M. Parkinson’s disease and insomnia. Neurol Sci. 2015;36(11):2003–10. 10.1007/s10072-015-2288-9 .26099862

3.Postuma RB Berg D Advances in markers of prodromal Parkinson disease Nat Rev Neurol 2016 12 11 622 634 10.1038/nrneurol.2016.152 27786242 Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol. 2016;12(11):622–34. 10.1038/nrneurol.2016.152 .27786242

4.Lysen TS Darweesh SK Ikram MK Luik AI Ikram MA Sleep and risk of parkinsonism and Parkinson’s disease: a population-based study Brain 2019 142 7 2013 22 10.1093/brain/awz113 31038176 PMC6911221 Lysen TS, Darweesh SK, Ikram MK, Luik AI, Ikram MA. Sleep and risk of parkinsonism and Parkinson’s disease: a population-based study. Brain. 2019;142(7):2013–22. 10.1093/brain/awz113 .PMC6911221 31038176

5.Xu Z Anderson KN Saffari SE Lawson RA Chaudhuri KR Brooks D Progression of sleep disturbances in Parkinson’s disease: a 5-year longitudinal study J Neurol 2021 268 1 312 20 10.1007/s00415-020-10140-x 32804280 PMC7815601 Xu Z, Anderson KN, Saffari SE, Lawson RA, Chaudhuri KR, Brooks D, et al. Progression of sleep disturbances in Parkinson’s disease: a 5-year longitudinal study. J Neurol. 2021;268(1):312–20. 10.1007/s00415-020-10140-x .PMC7815601 32804280

6.Ylikoski A Martikainen K Partinen M Parkinson’s disease and restless legs syndrome Eur Neurol 2015 73 3-4 212 9 10.1159/000375493 25792198 Ylikoski A, Martikainen K, Partinen M. Parkinson’s disease and restless legs syndrome. Eur Neurol. 2015;73(3–4):212–9. 10.1159/000375493 .25792198

7.Partinen E Ylikoski A Sieminski M Partinen M Impact of REM sleep behavior and sleep talking on mortality in Parkinson’s disease Cureus 2024 16 1 e52565 10.7759/cureus.52565 38249652 PMC10800163 Partinen E, Ylikoski A, Sieminski M, Partinen M. Impact of REM sleep behavior and sleep talking on mortality in Parkinson’s disease. Cureus. 2024;16(1):e52565. 10.7759/cureus.52565 .PMC10800163 38249652

8.Partinen E Inoue Y Sieminski M Merikanto I Bjorvatn B Bolstad CJ Restless legs symptoms increased during COVID-19 pandemic. International ICOSS-survey Sleep Med 2024 119 389 98 10.1016/j.sleep.2024.04.016 38772220 Partinen E, Inoue Y, Sieminski M, Merikanto I, Bjorvatn B, Bolstad CJ, et al. Restless legs symptoms increased during COVID-19 pandemic. International ICOSS-survey. Sleep Med. 2024;119:389–98. 10.1016/j.sleep.2024.04.016 .38772220

9.Iranzo A Cochen De Cock V Fantini ML Pérez-Carbonell L Trotti LM Sleep and sleep disorders in people with Parkinson’s disease Lancet Neurol 2024 23 9 925 37 10.1016/S1474-4422(24)00170-4 38942041 Iranzo A, Cochen De Cock V, Fantini ML, Pérez-Carbonell L, Trotti LM. Sleep and sleep disorders in people with Parkinson’s disease. Lancet Neurol. 2024;23(9):925–37. 10.1016/S1474-4422(24)00170-4 .38942041

10.Chen Y Gao Y Sun X Wang BH Qin L Wu IX Association between sleep factors and Parkinson’s disease: a prospective study based on 409,923 UK Biobank participants Neuroepidemiology 2023 57 5 293 303 10.1159/000530982 37231899 Chen Y, Gao Y, Sun X, Wang BH, Qin L, Wu IX, et al. Association between sleep factors and Parkinson’s disease: a prospective study based on 409,923 UK Biobank participants. Neuroepidemiology. 2023;57(5):293–303. 10.1159/000530982 .37231899

11.Partinen E Ylikoski A Sieminski M Kaps M Partinen M Hublin C Sleep duration, chronotype, and mortality in Parkinson’s disease: a prospective cohort study Nat Sci Sleep 2026 18 568358 10.2147/NSS.S568358 41858716 PMC12997261 Partinen E, Ylikoski A, Sieminski M, Kaps M, Partinen M, Hublin C. Sleep duration, chronotype, and mortality in Parkinson’s disease: a prospective cohort study. Nat Sci Sleep. 2026;18:568358. 10.2147/NSS.S568358 .PMC12997261 41858716

12.Parkinson’s Disease. Current care guidelines. Finnish Medical Society Duodecim. Published March 28, 2022. https://www.kaypahoito.fi/hoi50042. Accessed 4 Aug 2026.

13.Gelb DJ Oliver E Gilman S Diagnostic criteria for Parkinson disease Arch Neurol 1999 56 1 33 39 10.1001/archneur.56.1.33 9923759 Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9. 10.1001/archneur.56.1.33 .9923759

14.Partinen M Gislason T Basic Nordic Sleep Questionnaire (BNSQ): a quantitated measure of subjective sleep complaints J Sleep Res 1995 4 s1 S1 150 5 10.1111/j.1365-2869.1995.tb00205.x 10607192 Partinen M, Gislason T. Basic Nordic Sleep Questionnaire (BNSQ): a quantitated measure of subjective sleep complaints. J Sleep Res. 1995;4(s1 S1):150–5. 10.1111/j.1365-2869.1995.tb00205.x .10607192

15.Ylikoski A Martikainen K Partinen M Parasomnias and isolated sleep symptoms in Parkinson’s disease: a questionnaire study on 661 patients J Neurol Sci 2014 346 1-2 204 8 10.1016/j.jns.2014.08.025 25201715 Ylikoski A, Martikainen K, Partinen M. Parasomnias and isolated sleep symptoms in Parkinson’s disease: a questionnaire study on 661 patients. J Neurol Sci. 2014;346(1–2):204–8. 10.1016/j.jns.2014.08.025 .25201715

16.Heun R Burkart M Maier W Bech P Internal and external validity of the WHO Well-Being Scale in the elderly general population Acta Psychiatr Scand 1999 99 3 171 8 10.1111/j.1600-0447.1999.tb00973.x 10100911 Heun R, Burkart M, Maier W, Bech P. Internal and external validity of the WHO Well-Being Scale in the elderly general population. Acta Psychiatr Scand. 1999;99(3):171–8. 10.1111/j.1600-0447.1999.tb00973.x .10100911

17.Global recommendations on physical activity for health. World Health Organization. 2010. https://www.who.int/publications/i/item/9789241599979. Accessed 4 Aug 2026.26180873

18.Tomlinson CL Stowe R Patel S Rick C Gray R Clarke CE Systematic review of levodopa dose equivalency reporting in Parkinson’s disease Mov Disord 2010 25 15 2649 2653 10.1002/mds.23429 21069833 Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53. 10.1002/mds.23429 .21069833

19.Keltikangas-Järvinen L Rimon R Rimon’s brief depression scale, a rapid method for screening depression Psychol Rep 1987 60 1 111 9 10.2466/pr0.1987.60.1.111 3562710 Keltikangas-Järvinen L, Rimon R. Rimon’s brief depression scale, a rapid method for screening depression. Psychol Rep. 1987;60(1):111–9. 10.2466/pr0.1987.60.1.111 .3562710

20.Johns MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale Sleep 1991 14 6 540 5 10.1093/sleep/14.6.540 1798888 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5. 10.1093/sleep/14.6.540 .1798888

21.Chung F Yegneswaran B Liao P Chung SA Vairavanathan S Islam S STOP questionnaire: a tool to screen patients for obstructive sleep apnea Anesthesiology 2008 108 5 812 821 10.1097/ALN.0b013e31816d83e4 18431116 Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812–21. 10.1097/ALN.0b013e31816d83e4 .18431116

22.Allen RP Picchietti D Hening WA Trenkwalder C Walters AS Montplaisi J Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003 4 2 101 19 10.1016/S1389-9457(03)00010-8 14592341 Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J; Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19. 10.1016/S1389-9457(03)00010-8 .
14592341

23.Stiasny-Kolster K Mayer G Schäfer S Möller JC Heinzel-Gutenbrunner M Oertel WH The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument Mov Disord 2007 22 16 2386 2393 10.1002/mds.21740 17894337 Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord. 2007;22(16):2386–93. 10.1002/mds.21740 .17894337

24.Bastien CH Vallières A Morin CM Validation of the Insomnia Severity Index as an outcome measure for insomnia research Sleep Med 2001 2 4 297 307 10.1016/S1389-9457(00)00065-4 11438246 Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. 10.1016/S1389-9457(00)00065-4 .11438246

25.Li J Vitiello MV Gooneratne NS Sleep in normal aging Sleep Med Clin 2022 17 2 161 171 10.1016/j.jsmc.2022.02.007 35659071 Li J, Vitiello MV, Gooneratne NS. Sleep in normal aging. Sleep Med Clin. 2022;17(2):161–71. 10.1016/j.jsmc.2022.02.007 .35659071

26.Howard C Mukadam N Hui EK Livingston G The effects of sleep duration on the risk of dementia incidence in short and long follow-up studies: a systematic review and meta-analysis Sleep Med 2024 124 522 30 10.1016/j.sleep.2024.10.022 39442346 Howard C, Mukadam N, Hui EK, Livingston G. The effects of sleep duration on the risk of dementia incidence in short and long follow-up studies: a systematic review and meta-analysis. Sleep Med. 2024;124:522–30. 10.1016/j.sleep.2024.10.022 .39442346

27.Maggi G Vitale C Cerciello F Santangelo G Sleep and wakefulness disturbances in Parkinson’s disease: a meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia Sleep Med Rev 2023 68 101759 10.1016/j.smrv.2023.101759 36708642 Maggi G, Vitale C, Cerciello F, Santangelo G. Sleep and wakefulness disturbances in Parkinson’s disease: a meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Med Rev. 2023;68:101759. 10.1016/j.smrv.2023.101759 .36708642

28.Schormair B Zhao C Bell S Didriksen M Nawaz MS Schandra N Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction Nat Genet. 2024 56 6 1090 9 10.1038/s41588-024-01763-1 38839884 PMC11176086 Schormair B, Zhao C, Bell S, Didriksen M, Nawaz MS, Schandra N, et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nat Genet. 2024;56(6):1090–9. 10.1038/s41588-024-01763-1 .PMC11176086 38839884

29.Moccia M Erro R Picillo M Santangelo G Spina E Allocca R A four-year longitudinal study on restless legs syndrome in Parkinson disease Sleep 2016 39 2 405 412 10.5665/sleep.5452 26564123 PMC4712388 Moccia M, Erro R, Picillo M, Santangelo G, Spina E, Allocca R, et al. A four-year longitudinal study on restless legs syndrome in Parkinson disease. Sleep. 2016;39(2):405–12. 10.5665/sleep.5452 .PMC4712388 26564123

30.Yang X Liu B Shen H Li S Zhao Q An R Prevalence of restless legs syndrome in Parkinson’s disease: a systematic review and meta-analysis of observational studies Sleep Med 2018 43 40 46 10.1016/j.sleep.2017.11.1146 29482811 Yang X, Liu B, Shen H, Li S, Zhao Q, An R, et al. Prevalence of restless legs syndrome in Parkinson’s disease: a systematic review and meta-analysis of observational studies. Sleep Med. 2018;43:40–6. 10.1016/j.sleep.2017.11.1146 .29482811

31.Sauerbier A Jenner P Todorova A Chaudhuri KR Non motor subtypes and Parkinson’s disease Parkinsonism Relat Disord 2016 22 Suppl 1 S41 S46 10.1016/j.parkreldis.2015.09.027 26459660 Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41–6. 10.1016/j.parkreldis.2015.09.027 .26459660

Come citare questo studio

Eemil Partinen, Ari Ylikoski, Christer Hublin, Markku Partinen. (2026). Changes in sleep characteristics in Parkinson's disease: a prospective 5-year follow-up study.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. DOI: 10.1007/s44470-026-00169-6

Consulta la pubblicazione originale ↗